secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0000950170-25-015851
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q4 net loss $6.6M; cash $24.1M, ORLYNVAH approved
---------------------------------------------------------------------

- Net loss Q4 2024 $6.6M vs $12.4M in Q4 2023; full year $24.8M vs $38.4M.
- Cash and equivalents $24.1M at Dec 31, 2024; including $4.8M ATM proceeds Jan-Feb 2025, runway into H2 2025.
- R&D expenses fell to $1.3M in Q4 2024 from $9.7M, driven by lower REASSURE trial costs.
- ORLYNVAH (sulopenem etzadroxil/probenecid) approved by FDA for uUTIs in Q4 2024; pre-commercialization underway.
- Repaid outstanding 6.500% Exchangeable Notes due 2025 in January 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/0000950170-25-015851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/itrm-20250207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-015851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer